Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
J. immunotherap. cancer; 11 (10), 2023
Since the first approval for immune checkpoint inhibitors
(ICIs) for the treatment of cutaneous melanoma more than
a decade ago, immunotherapy has completely transformed
the treatment landscape of this chemotherapy-resistant
disease. Combination regimens including ICIs directed
against programmed cell de...